XOMA (NASDAQ:XOMAP – Get Free Report) is projected to post its results before the market opens on Thursday, March 5th. Analysts expect XOMA to post earnings of ($0.11) per share and revenue of $11.13 million for the quarter.
XOMA Stock Down 0.4%
XOMA stock opened at $25.84 on Thursday. XOMA has a one year low of $24.96 and a one year high of $30.00. The business has a fifty day moving average price of $26.40 and a 200-day moving average price of $26.39.
XOMA Company Profile
XOMA Corporation (NASDAQ: XOMAP) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutic antibodies for autoimmune and inflammatory diseases. The company leverages proprietary antibody-generation technologies—including ribosome display and phage display—to identify and optimize human monoclonal antibodies with high specificity and favorable pharmacological profiles.
Its lead clinical program is an interleukin-1 beta modulator being evaluated in patients with rare and severe inflammatory conditions.
Further Reading
- Five stocks we like better than XOMA
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- ALERT: Drop these 5 stocks before the market opens tomorrow!
- Elon Musk: This Could Turn $100 into $100,000
- Read this or regret it forever
- The Next Commodity Crunch (bigger than oil?)
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.
